Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review

Table 1 Mean survival time after specific treatment modalities for local and systemic hepatocellular carcinoma recurrence in liver transplantation patients

Type of treatment for HCC recurrence in LT patients	No. of patients	Median survival1 (mo) (weighted mean ± SD)	Ref.
Loco-regional treatments for resectable local recurrence of HCC
Surgery	27	42 ± 24.45	Bates et al[38]
			Kornberg et al[50]
			Pfiffer et al[54]
			Kim et al[47]
			Chen et al[77]
			Sommacale et al[74]
TACE	40	11.2 ± 8.81	Tan et al[80]
			Kim et al[47]
			Pfiffer et al[54]
			Carr[39]
			Chen et al[77]
			Yamagami et al[64]
Systemic treatments for unresectable, advanced, multifocal recurrence of HCC
Sorafenib	76	12.1 ± 9.95	Tan et al[80]
			Yoon et al[65]
			Pfiffer et al[54]
			Staufer et al[76]
			Sposito et al[79]
			Pfeiffenberger et al[78]
			Alsina et al[73]
Sorafenib + mTOR	68	18.2 ± 6.53	Waidmann et al[34]
			Gomez-Martin et al[45]
			Weimann et al[63]
			Staufer et al[76]
			Sotiropoulos et al[58]
Systemic chemotherapy	35	5.79 ± 2.7	Lee et al[84]
			Kim et al[47]
Best supportive care	54	3.3 ± 2.12	Kim et al[47]
			Pfiffer et al[54]
			Yoon et al[82]
			Sposito et al[79]

¹Weighted mean survival (standard deviation) is calculated from the studies that reported the median survival in months from HCC recurrence diagnosis. TACE: Transarterial chemoembolization; HCC: Hepatocellular carcinoma; LT: Liver transplantation; mTOR: Mammalian target of rapamycin.